Royalty Pharma plc: revenue
Revenue for Royalty Pharma plc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Royalty Pharma plc financial histories
What this measure means
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
Exact concept: us-gaap:Revenues. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 2,378,193,000 | USD | 2026-02-11 | 10-K · 0001802768-26-000003 |
| 2024-01-01 | 2024-12-31 | 2,263,576,000 | USD | 2026-02-11 | 10-K · 0001802768-26-000003 |
| 2023-01-01 | 2023-12-31 | 2,354,554,000 | USD | 2026-02-11 | 10-K · 0001802768-26-000003 |
| 2022-01-01 | 2022-12-31 | 2,237,215,000 | USD | 2025-02-12 | 10-K · 0001802768-25-000010 |
| 2021-01-01 | 2021-12-31 | 2,289,463,000 | USD | 2024-02-15 | 10-K · 0001802768-24-000012 |
| 2020-01-01 | 2020-12-31 | 2,122,353,000 | USD | 2023-02-15 | 10-K · 0001802768-23-000007 |
| 2019-01-01 | 2019-12-31 | 1,814,254,000 | USD | 2022-02-15 | 10-K · 0001802768-22-000011 |
| 2018-01-01 | 2018-12-31 | 1,794,894,000 | USD | 2021-02-24 | 10-K · 0001802768-21-000006 |
Related financial histories
- Royalty Pharma plc: total assets
- Royalty Pharma plc: total liabilities
- Royalty Pharma plc: cash and cash equivalents
- Royalty Pharma plc: net income or loss
- Royalty Pharma plc: operating cash flow
- Royalty Pharma plc: financing cash flow
- Royalty Pharma plc: investing cash flow
- Royalty Pharma plc: retained earnings or deficit
- Royalty Pharma plc: basic weighted-average shares
- Royalty Pharma plc: diluted weighted-average shares
- Royalty Pharma plc: basic earnings per share
- Royalty Pharma plc: diluted earnings per share
- Royalty Pharma plc: share-based compensation expense
- Royalty Pharma plc: operating income or loss
- Royalty Pharma plc: current assets
- Royalty Pharma plc: interest expense
- Royalty Pharma plc: current liabilities
- Royalty Pharma plc: net finite-lived intangible assets
- Royalty Pharma plc: common-stock repurchase payments
- Royalty Pharma plc: research and development expense
Inspect the source
- Entity
- Royalty Pharma plc / CIK 0001802768
- Captured
- 2026-09-19T11:21:26.675Z
- SEC response SHA-256
c262dd24bf00deafc75f2a9b70143a098ed4f46c24502075639f3d798cb3cb15
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001802768.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))